IGM-2537

N/A

Report date: 2026/03/19 17:15:18

Base Information

Drug NameIGM-2537

Drug Alias NameIGM-2537

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD123Anti-CD3

TargetsInterleukin-3 receptor subunit alphaT cell surface glycoprotein CD3

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcutePrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesIgm Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIgm Biosciences Inc

Active IndicationsN/A

Inactive IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcutePrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A